Tesaro, a biotech focused on the treatment of chemotherapy-induced symptoms, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Waltham, MA-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol TSRO. Citi, Morgan Stanley and Leerink Swann are the joint bookrunners on the deal.
